ArticleTranslational oncology2025

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression.

Jianfeng Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.